A dataset of cancer gene mutation rates and associated analysis in CN and U.S. patient population

We integrated the tumor epidemiological statistics with cancer gene mutation rates identified in 11,948 cancer patients to determine their weighted proportions within the Chinese cancer patients. TP53 (51.4%), LRP1B (13.4%), PIK3CA (11.6%), KRAS (11.1%), EGFR (10.6%), and APC (10.5%) were identified as the top mutated cancer genes in China. Additionally, 18 common cancer types from both China and U.S. cohorts were analyzed and classified into three patterns principally based upon TP53 mutation rates: TP53-Top, TP53-Plus, and Non-TP53.

Next, corresponding similarities and prominent differences were identified upon comparing the mutational profiles from both cohorts. Finally, the potential population-specific and environmental risk factors underlying the disparities in cancer gene mutation rates between the U.S. and China were analyzed.